Related Experiment Video
Updated: Jan 6, 2026

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications
Published on: October 20, 2023
QSP-Copilot: An AI-Augmented Platform for Accelerating Quantitative Systems Pharmacology Model Development
1Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
Abstract:
Quantitative Systems Pharmacology (QSP) is a powerful approach to provide decision-making support throughout the drug development process. QSP comes with many challenges in model development, validation, and applications. Traditional QSP workflows are limited by slow knowledge integration, labor-intensive model construction, inconsistent validation practices, and restricted scalability. In this work, we introduce QSP-Copilot, the first end-to-end AI-augmented solution designed to improve QSP modeling workflows by integrating a multi-agent system utilizing large language models (LLMs). QSP-Copilot provides modular support from project scoping and model structuring to model evaluation and reporting. Through the automation of routine tasks, QSP-Copilot reduces model development time by approximately 40% and improves methodological transparency through systematic documentation of literature sources and modeling assumptions. We demonstrate QSP-Copilot's application for two rare diseases of blood coagulation and Gaucher disease. In the blood coagulation case, automated extraction from ten peer-reviewed articles yielded 179 biological entity interaction pairs; out of these, only 105 unique mechanisms were retained after standardization. For Gaucher disease, screening nine articles produced 151 pairs, which were consolidated into 68 distinct biological interactions following the same post-processing workflow. The extraction precision for blood coagulation and Gaucher disease is 99.1% and 100.0%, respectively. QSP-Copilot extractions can be incorporated into effect diagrams with minimal expert filtering, significantly reducing the manual curation burden. The integration of AI-augmented workflows like QSP-Copilot represents a pivotal shift toward enhanced scalability and impact for QSP across the drug development pipelines, especially in disease areas where biological knowledge is sparse, such as rare diseases.
More Related Videos
05:47In Silico Modeling Method for Computational Aquatic Toxicology of Endocrine Disruptors: A Software-Based Approach Using QSAR Toolbox
Published on: August 28, 2019
05:50Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro
Published on: September 26, 2025
Related Concept Videos
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
Model Approaches for Pharmacokinetic Data: Compartment Models
Two primary types of compartment models are recognized: mammillary and catenary. The more...
Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Model Approaches for Pharmacokinetic Data: Physiological Models
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.